Tenaya Therapeutics (TNYA) Is Down 39.7% After Cardiac Gene Therapy Milestones And $60M Fundraise - What's Changed [Yahoo! Finance]
Tenaya Therapeutics, Inc. (TNYA)
Company Research
Source: Yahoo! Finance
that the FDA has lifted the clinical hold on its MyPEAK-1 trial of TN-201 for MYBPC3-associated hypertrophic cardiomyopathy, while also completing a US$60,000,000 units offering to fund these programs. Together, these updates highlight Tenaya's push to advance first-in-class cardiac gene therapies targeting the genetic root of serious inherited heart diseases, backed by fresh capital and regulatory momentum. Next, we'll examine how the encouraging TN-401 arrhythmia data shapes Tenaya's investment narrative in light of the recent share price decline. The end of cancer? These 29 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's. To own Tenaya Therapeutics, you have to believe that its AAV9 gene therapy platform can turn early biological signals in rare inherited cardiomyopathies into approvable, one-time treatments before the cash runs dry. The latest RIDGE-1 TN-401 data and the FDA lifting the MyPEA
Show less
Read more
Impact Snapshot
Event Time:
TNYA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TNYA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TNYA alerts
High impacting Tenaya Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
TNYA
News
- Tenaya Therapeutics (NASDAQ:TNYA) had its price target lowered by analysts at HC Wainwright from $5.00 to $3.00. They now have a "buy" rating on the stock.MarketBeat
- Tenaya Therapeutics (NASDAQ:TNYA) had its price target lowered by analysts at Chardan Capital from $9.00 to $8.00. They now have a "buy" rating on the stock.MarketBeat
- Tenaya Therapeutics Announces Pricing of Public OfferingGlobeNewswire
- Tenaya Therapeutics Announces Rapid Resolution and Lifting of Clinical Hold for MyPEAK-1™ Phase 1b/2a Clinical Trial of TN-201 Gene Therapy [Yahoo! Finance]Yahoo! Finance
- Tenaya Therapeutics Announces Proposed Public Offering [Yahoo! Finance]Yahoo! Finance
TNYA
Earnings
- 11/10/25 - Beat
TNYA
Sec Filings
- 12/12/25 - Form 8-K
- 12/12/25 - Form 424B5
- 12/11/25 - Form 424B5
- TNYA's page on the SEC website